Steven R Steinhubl

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi request reprint Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
    Steven R Steinhubl
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    J Am Coll Cardiol 47:939-43. 2006
  2. ncbi request reprint Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect
    Steven R Steinhubl
    Division of Cardiology, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Thromb Res 121:527-34. 2008
  3. ncbi request reprint Platelets as mediators of inflammation
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 South Limestone Avenue, 326 Charles T Wellington Building, Lexington, KY 40536 0200, USA
    Hematol Oncol Clin North Am 21:115-21. 2007
  4. ncbi request reprint The role of the platelet in the pathogenesis of atherothrombosis
    Steven R Steinhubl
    The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington, Kentucky 40536 0284, USA
    Am J Cardiovasc Drugs 5:399-408. 2005
  5. ncbi request reprint Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 S Limestone Ave, 326 Charles T Wethington Bldg, Lexington, KY 40536, USA
    J Thromb Thrombolysis 26:8-13. 2008
  6. ncbi request reprint Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
  7. ncbi request reprint Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0284, USA
    Am Heart J 154:3-11. 2007
  8. ncbi request reprint Risk stratifying the acute coronary syndrome patient: a focus on treatable risk
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 8:S3-8. 2007
  9. pmc Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and Lexington Veterans Administration Hospital, Lexington, Kentucky, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
  10. pmc Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009

Collaborators

Detail Information

Publications74

  1. ncbi request reprint Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
    Steven R Steinhubl
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    J Am Coll Cardiol 47:939-43. 2006
    ..This study sought to determine the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (PCI) in patients enrolled in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial...
  2. ncbi request reprint Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect
    Steven R Steinhubl
    Division of Cardiology, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Thromb Res 121:527-34. 2008
    ..As many individuals treated acutely with cangrelor will often be treated long-term with a thienopyridine, it is important to determine the effects of concurrent cangrelor and clopidogrel administration...
  3. ncbi request reprint Platelets as mediators of inflammation
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 South Limestone Avenue, 326 Charles T Wellington Building, Lexington, KY 40536 0200, USA
    Hematol Oncol Clin North Am 21:115-21. 2007
    ....
  4. ncbi request reprint The role of the platelet in the pathogenesis of atherothrombosis
    Steven R Steinhubl
    The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington, Kentucky 40536 0284, USA
    Am J Cardiovasc Drugs 5:399-408. 2005
    ..Elucidation of the multiple mechanisms involved in platelet thrombus formation provides opportunities for selectively inhibiting the pathways most relevant to the pathophysiology of atherothrombosis...
  5. ncbi request reprint Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 S Limestone Ave, 326 Charles T Wethington Bldg, Lexington, KY 40536, USA
    J Thromb Thrombolysis 26:8-13. 2008
    ....
  6. ncbi request reprint Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
    ....
  7. ncbi request reprint Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0284, USA
    Am Heart J 154:3-11. 2007
    ....
  8. ncbi request reprint Risk stratifying the acute coronary syndrome patient: a focus on treatable risk
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 8:S3-8. 2007
    ..Although the ACC/AHA Guidelines combine patients with unstable angina and NSTEMI, it is essential to evaluate troponin status in order to optimize patient outcomes and safety in the treatment of suspected ACS...
  9. pmc Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and Lexington Veterans Administration Hospital, Lexington, Kentucky, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
    ..To determine if salivary biomarkers demonstrate utility for identifying aspects of myocardial necrosis...
  10. pmc Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009
    ..Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes...
  11. ncbi request reprint Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 7:S12-9. 2006
    ..All of this benefit was confined to the patients with elevated troponin levels. The data indicate that troponin can be used as a biomarker to identify patients most likely to benefit from the addition of a GP IIb/IIIa antagonist...
  12. doi request reprint Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis
    Jeffrey S Berger
    Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 52:1693-701. 2008
    ..S. hospitals...
  13. ncbi request reprint Platelet activation and its patient-specific consequences
    Susan S Smyth
    Division of Cardiology, University of Kentucky, Lexington, USA
    Thromb Res 122:435-41. 2008
    ..These phenomena may help to explain differences in experimental arterial thrombosis observed in individuals...
  14. ncbi request reprint Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
    ..Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied...
  15. ncbi request reprint Oral antiplatelet therapy for percutaneous coronary revascularization
    Hussam Hamdalla
    Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA
    Catheter Cardiovasc Interv 69:637-42. 2007
    ..This review will highlight these data as well as emphasize the gaps in our understanding. (c) 2007 Wiley-Liss, Inc...
  16. doi request reprint Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] tri
    Arijit Dasgupta
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Am J Cardiol 103:1359-63. 2009
    ..In conclusion, this post hoc analysis suggested that clopidogrel may be harmful in patients with diabetic nephropathy. Additional studies are needed to investigate this possible interaction...
  17. ncbi request reprint The evolving algorithm concerning higher-risk PCI (TEACH-PCI). Introduction
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 8:S1-2. 2007
  18. ncbi request reprint Incidence and prevention of ischemic stroke following myocardial infarction: review of current literature
    Monisha Dutta
    Department of Neurology, University of Kentucky, Lexington, KY 40536, USA
    Cerebrovasc Dis 22:331-9. 2006
    ..We discuss the incidence, pathophysiology, and management options of non-hemorrhagic stroke following a myocardial infarction...
  19. doi request reprint G-protein-coupled receptors as signaling targets for antiplatelet therapy
    Susan S Smyth
    Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 29:449-57. 2009
    ..The identification and development of new agents directed against specific platelet signaling pathways may offer an advantage in preventing thrombotic events while minimizing bleeding risk...
  20. ncbi request reprint Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization
    Pranab Das
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky and the VA Medical Center, Lexington, Kentucky 40536 0200, USA
    J Invasive Cardiol 18:405-8. 2006
    ..We sought to identify the impact of stent type (DES versus BMS) on TVR and other cardiac adverse events in ESRD patients...
  21. pmc Oral fluids that detect cardiovascular disease biomarkers
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012
    ..The aim of this study was to determine the utility of oral fluids for assessment of coronary and cardiovascular (CV) health...
  22. ncbi request reprint Antiplatelet therapy: aspirin
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, 349 Burnett Womack Building, Chapel Hill, NC 27599, USA
    J Invasive Cardiol 15:11B-16B; discussion 16B. 2003
  23. doi request reprint Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
    J Thromb Thrombolysis 31:139-45. 2011
    ..3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event...
  24. ncbi request reprint Clopidogrel: how good is it and how does it work?
    Richard A Santa-Cruz
    Division of Cardiology, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599 7075, USA
    Curr Cardiol Rep 6:264-8. 2004
    ....
  25. ncbi request reprint Heparin-induced thrombocytopenia and cardiovascular diseases
    Pranab Das
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
    Am Heart J 152:19-26. 2006
  26. ncbi request reprint Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002
  27. pmc Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data
    Alison L Bailey
    Division of Cardiovascular Medicine, The Gill Heart Institute, The University of Kentucky, Lexington, KY, USA
    CMAJ 174:1431-2. 2006
  28. ncbi request reprint Variable response to antiplatelet therapy: what does it mean to clinicians?
    Nezar Falluji
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, USA
    Cleve Clin J Med 74:49-55. 2007
    ....
  29. ncbi request reprint Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
    ..More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose...
  30. ncbi request reprint Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Steven R Steinhubl
    Steven R Steinhubl
    Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA
    Am J Cardiovasc Drugs 6:415-6. 2006
  31. pmc Impact of genetic polymorphisms on clinical response to antithrombotics
    Kena J Lanham
    Pharmacy Services, UK HealthCare, University of Kentucky, Lexington, Kentucky, USA Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
    Pharmgenomics Pers Med 3:87-99. 2010
    ....
  32. doi request reprint Cangrelor in percutaneous coronary intervention
    Julie H Oestreich
    725 Rose Street, College of Pharmacy, University of Kentucky, Lexington, KY 40514, USA
    Expert Rev Clin Pharmacol 2:137-45. 2009
    ..These unique characteristics make cangrelor a promising agent for use in cardiovascular patients undergoing percutaneous coronary intervention. ..
  33. doi request reprint Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
    John W Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    Circulation 118:1705-12. 2008
    ....
  34. ncbi request reprint Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
    Steven R Steinhubl
    J Am Coll Cardiol 42:1336; author reply 1336-7. 2003
  35. ncbi request reprint Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  36. ncbi request reprint Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    J Invasive Cardiol 19:287-90. 2007
    ..The relationship between target vessel revascularization (TVR) and ischemic events in patients treated with aspirin and clopidogrel or aspirin alone from 1 month to 1 year after PCI has not been studied...
  37. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  38. ncbi request reprint Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials
    Raphaelle Dumaine
    Centre Hospitalier Universitaire Pitie Salpetriere, Institute of Cardiology, Bureau 2 236, 47 Blvd de l Hopital, 75013, Paris, France
    Arch Intern Med 167:2423-30. 2007
    ..Our objective was to perform a meta-analysis of randomized trials comparing the efficacy and safety of LMWH vs UFH as anticoagulants in the setting of PCI...
  39. doi request reprint Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  40. ncbi request reprint An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  41. doi request reprint The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Patricia J M Best
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 155:687-93. 2008
    ..Therapy with clopidogrel decreases adverse events in large patient populations. Therefore, we sought to determine the efficacy and safety of long-term clopidogrel therapy in patients with CKD...
  42. doi request reprint Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use
    Marc S Sabatine
    Cardiovascular Division, Department of Medicine, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:910-7. 2008
    ..However, the need for clopidogrel pretreatment is debated in patients receiving a glycoprotein IIb/IIIa inhibitor (GPI)...
  43. ncbi request reprint Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial
    Jacqueline Saw
    Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 50:291-5. 2007
    ..The purpose of this study was to evaluate the potential impact of clopidogrel and statin interaction in a randomized, placebo-controlled trial with long-term follow-up...
  44. doi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  45. ncbi request reprint Platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Am Coll Cardiol 50:1822-34. 2007
    ....
  46. ncbi request reprint Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy
    W H Wilson Tang
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 153:36-41. 2007
    ..The comparative prognostic values between NT-proBNP levels and left ventricular ejection fraction (LVEF) in the nonurgent PCI setting are unclear...
  47. ncbi request reprint Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:623-5. 2004
    ..4% vs 21.7%)...
  48. ncbi request reprint Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 110:994-8. 2004
    ..Despite significant pharmacological and mechanical advancements in PCI, uncertainty remains about the optimal activated clotting time (ACT) for prevention of ischemic or hemorrhagic complications...
  49. ncbi request reprint Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial
    James J Ferguson
    JAMA 292:45-54. 2004
    ..Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy...
  50. ncbi request reprint Antiplatelet effect of aspirin in patients with cerebrovascular disease
    Jay S Varanasi
    Stroke 35:e144-5. 2004
  51. ncbi request reprint Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes
    Jo E Rodgers
    Division of Pharmacotherapy, University of North Carolina, Chapel Hill 27599 7360, USA
    Expert Rev Cardiovasc Ther 1:507-21. 2003
    ....
  52. ncbi request reprint Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 147:463-7. 2004
    ..We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement...
  53. ncbi request reprint Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 146:713-20. 2003
    ..We assessed antiplatelet properties of clopidogrel with aspirin (C+A) versus aspirin alone (A) in patients with CHF with heightened platelet activity...
  54. ncbi request reprint Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    Jacqueline Saw
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:921-4. 2003
    ..However, the clinical impact of this interaction has not been evaluated...
  55. ncbi request reprint Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort
    Steven R Steinhubl
    Am Heart J 146:213-4. 2003
  56. ncbi request reprint Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists
    Steven R Steinhubl
    Department of Medicine, University of North Carolina, Chapel Hill, 27599 7075, USA
    Coron Artery Dis 14:381-6. 2003
  57. ncbi request reprint Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested
    Victor L Serebruany
    Circulation 107:1568-9. 2003
  58. ncbi request reprint Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction
    Ara M Maranian
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA
    Curr Cardiol Rep 4:313-9. 2002
    ..This review summarizes recently published trials using combination thrombolytic and GP IIb/IIIa receptor inhibitor therapy in the treatment of acute MI...
  59. ncbi request reprint Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study
    Victor L Serebruany
    HeartDrug Research, LLC, Baltimore, MD, USA
    Arch Intern Med 164:2051-7. 2004
    ..We sought to address this issue prospectively by performing serial measurements of 19 platelet characteristics using conventional aggregometry, rapid analyzers, and flow cytometry...
  60. ncbi request reprint Risk reduction with long-term clopidogrel following percutaneous coronary intervention
    Steven R Steinhubl
    Eur Heart J 25:2169-70; author reply 2170-1. 2004
  61. ncbi request reprint Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 44:2133-6. 2004
    ..We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of pretreatment with a 600-mg loading dose of clopidogrel...
  62. ncbi request reprint Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction
    Eric Van De Graaff
    Nebraska Heart Institute, Omaha, Neb, USA
    Stroke 37:2546-51. 2006
    ..The influence of the timing and type of revascularization on risk of ischemic stroke in the patient with MI has not previously been assessed...
  63. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  64. ncbi request reprint Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 98:681-4. 2006
    ..A point-of-care assay can identify subjects who may recover platelet function before 5 days after discontinuation or, in contrast, have persistent PI despite discontinuation...
  65. ncbi request reprint Clopidogrel-statin interaction: a mountain or a mole hill?
    Steven R Steinhubl
    Am Heart J 152:200-3. 2006
  66. ncbi request reprint Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough
    Steven R Steinhubl
    JAMA 295:1581-2. 2006
  67. ncbi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  68. ncbi request reprint Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study
    Charles L Campbell
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
    Am Heart J 150:796-9. 2005
    ..N-Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platelets...
  69. ncbi request reprint A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  70. ncbi request reprint Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?
    David J Moliterno
    JAMA 294:1271-3. 2005
  71. ncbi request reprint Resistance to antiplatelet resistance is it justified?
    Steven R Steinhubl
    J Am Coll Cardiol 45:1757-8. 2005
  72. ncbi request reprint The use of anti-inflammatory analgesics in the patient with cardiovascular disease: what a pain
    Steven R Steinhubl
    J Am Coll Cardiol 45:1302-3. 2005
  73. ncbi request reprint Variability in platelet responsiveness to clopidogrel among 544 individuals
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Building, 7600 Osler Drive, Towson, MD 21204, USA
    J Am Coll Cardiol 45:246-51. 2005
    ..We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population...
  74. ncbi request reprint The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy
    Guy L Wheeler
    Wake Forest University School of Medicine, Winston Salem, NC 27157 1045, USA
    Am Heart J 143:602-11. 2002
    ..Furthermore, a diminished degree of platelet inhibition is an independent predictor of adverse cardiac events, highlighting the need for accurate and precise monitoring of platelet function...